Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time–kill methodology

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America

Peter G. Pappas, Carol A. Kauffman, David R. Andes et al. · Clinical Infectious Diseases · 2009 · 3.2K citations · Full text

Pharmacy, Infectious Diseases, Microbiology +17

Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis

Peter G. Pappas, C. M. F. Rotstein, Robert F. Betts et al. · Clinical Infectious Diseases · 2007 · 632 citations · Full text

Medicine, Microbiology, Pharmacology +16

<i>Candida orthopsilosis</i> and <i>Candida metapsilosis</i> spp. nov. To Replace <i>Candida parapsilosis</i> Groups II and III

Arianna Tavanti, Amanda D. Davidson, Neil A. R. Gow et al. · Journal of Clinical Microbiology · 2005 · 599 citations · Full text

Life Sciences, Genetics, Microbiology +17

A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in <i>Candida parapsilosis</i> , <i>Candida orthopsilosis</i> , and <i>Candida metapsilosis</i> Accounts for Reduced Echinocandin Susceptibility

Guillermo García‐Effrón, Säntosh K. Katiyar, Steven Park et al. · Antimicrobial Agents and Chemotherapy · 2008 · 316 citations

Life Sciences, Infectious Diseases, Microbiology +17

A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

Robert F. Betts, Márcio Nucci, Deepak Talwar et al. · Clinical Infectious Diseases · 2009 · 213 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17